← Back to headlines
Analysts Maintain Positive Outlook on Protagonist Therapeutics and Bunzl
Investment firms Clear Street and Jefferies reiterated buy ratings for Protagonist Therapeutics, pointing to the commercial strength of its Mimrylo label. Meanwhile, Morningstar affirmed its support for Bunzl, noting that current share prices remain undervalued relative to the company's competitive advantages.
31 Aug, 17:55 — 31 Aug, 17:55
Sources
Showing 1 of 2 sources
Coverage Timeline
First report: morningstar · 31 Aug, 15:46|Full coverage: 2 · 2h|Window: 2h
Left-leaningCenterRight-leaning
